ArticleJournal of nanobiotechnology2025
AI-guided design of a CXCR4-targeted core-shell nanocarrier for co-delivery of berberine/paclitaxel in cancer therapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Paclitaxel Nanomedicines: Molecular Mechanisms of Drug Resistance, Tumor Microenvironment-Responsive Delivery, and Translational Challenges.International journal of molecular sciences · 2026Review
- Engineering smart polymeric lipid nanoparticles for breast cancer: AI-guided formulation design, biological barriers, and translational constraints.Journal of nanobiotechnology · 2026Review
- Therapeutic strategies for ischemic heart disease with natural product-based nanomedicines.Journal of nanobiotechnology · 2026Review
- Simulation-guided design of peptide-metal coordination interfaces for next-generation metallo-immunotherapy.Nano convergence · 2026Review
- Self-Assembled Berberine-Sinapic Acid Nanomedicine for Synergistic Chemotherapy.Molecules (Basel, Switzerland) · 2026Article
- Ligand-modified multifunctional liposome-based targeted delivery platform: a multimodal cancer combination therapy strategy.Theranostics · 2026Review
- Inhaled Targeted Nano-Drug Delivery Systems for COPD: Precision Solutions to Clinical Barriers.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
An integrated three-step artificial-intelligence (AI) workflow was developed to accelerate the design of a CXCR4-targeted, dual-drug nanocarrier for colorectal cancer therapy. The workflow combined AI-based drug synergy prediction, peptide ligand discovery, and formulation optimization to create a core-shell nanocarrier consisting of a mesoporous silica core coated with a liposomal shell, co-delivering berberine (BBR) and paclitaxel (PTX). The nanocarrier exhibited efficient drug loading, sustained release, and selective uptake by CXCR4-positive cancer cells. In vitro, it synergistically inhibited cancer proliferation and migration, while in vivo it produced pronounced tumor regression and reversal of tumor-associated splenomegaly without systemic toxicity. These findings demonstrate that AI-guided synergy scouting and modular nanocarrier engineering can yield a receptor-targeted combination therapy with translational potential for next-generation cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.